Capricor Therapeutics Inc (NASDAQ:CAPR) Given Average Rating of “Buy” by Brokerages

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been given an average rating of “Buy” by the five ratings firms that are covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have covered the stock in the last year is $19.80.

A number of brokerages have commented on CAPR. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. Maxim Group reissued a “buy” rating and set a $12.00 target price on shares of Capricor Therapeutics in a research note on Tuesday.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR traded up $0.76 during trading on Tuesday, reaching $5.17. The company’s stock had a trading volume of 1,332,870 shares, compared to its average volume of 343,455. The firm has a market cap of $165.33 million, a price-to-earnings ratio of -5.86 and a beta of 3.92. The firm has a 50 day moving average of $4.33 and a 200-day moving average of $5.17. Capricor Therapeutics has a 12 month low of $2.68 and a 12 month high of $7.28.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. Equities research analysts forecast that Capricor Therapeutics will post -1.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently added to or reduced their stakes in CAPR. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics in the second quarter worth approximately $426,000. Renaissance Technologies LLC grew its position in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares during the last quarter. Main Street Financial Solutions LLC raised its position in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares during the last quarter. Rhumbline Advisers acquired a new position in Capricor Therapeutics during the second quarter worth approximately $147,000. Finally, Bank of New York Mellon Corp lifted its holdings in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.